Aspin Pharma
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer with branded portfolios across gastroenterology, cardiology, neuropsychiatry, endocrinology and women’s health.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Aspin Pharma (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot No. 10 & 25, Sector 20, Korangi Industrial Area, Karachi 74900, Pakistan · 74900
- Website
- aspin.com.pk ↗
- Phone
- +92 21 111 515 515; +92 21 35045560-62
- info@aspin.com.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Impecin | Mupirocin | 2% w/w | Ointment | 15gm | 090851 | PKR 217.73 | PKR 14.52/g | No comparator |
| Iroxide | Iron polymaltose complex | 50 mg/mL + 50 mg | Oral drops | 15ml | 107671 | PKR 97.54 | PKR 6.50/mL | No comparator |
| Iroxide | Elemental Iron | 100 mg | Tablet | 30's | 112741 | PKR 458.20 | PKR 15.27/tablet | 12% above median |
| M-Span | Cefixime | 400 mg | Capsule | 5's | 098673 | PKR 592.03 | PKR 118.41/capsule | Near median |
| M-Span Dry | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 098672 | PKR 404.31 | PKR 13.48/mL | Near median |
| M-Span Dry Suspension100mg/5ml | Cefixime | 100 mg/5 mL | Dry suspension | 30ml | 098671 | PKR 330.39 | PKR 11.01/mL | 5% above median |
| Maldip | Dihydroartemisinin + Piperaquine | 40 mg + 320 mg | Tablet | 8's | 100142 | PKR 670.67 | PKR 83.83/tablet | Near median |
| Mi-Tazo | Piperacillin + tazobactam | 2 g + 0.25 g | Injection | 1's | 112713 | PKR 711.91 | PKR 711.91/vial/unit | Near median |
| Mi-Tazo | Piperacillin + tazobactam | 4.0 g + 0.5 g | Injection | 1's | 112714 | PKR 1,618.54 | PKR 1,618.54/vial/unit | Near median |
| Misort | Misoprostol | 200 mcg | Tablet | 28's | 100143 | PKR 574.79 | PKR 20.53/tablet | Near median |
| Misort | Misoprostol | 200 mcg | Tablet | 10's | 100143 | PKR 205.28 | PKR 20.53/tablet | Near median |
| Misort | Misoprostol | 100 mcg | Tablet | 10's | 103148 | PKR 118.91 | PKR 11.89/tablet | 5% below median |
| Morning Pill | Levonorgestrel | 0.75 mg | Tablet | 2's | 096248 | PKR 20.95 | PKR 10.48/tablet | 31% below median |
| Obsarib | Ribavirin | 600 mg | Tablet | 10's | 098669 | PKR 244.36 | PKR 24.44/tablet | Near median |
| Obsarib | Ribavirin | 500 mg | Tablet | 10's | 098670 | PKR 213.71 | PKR 21.37/tablet | 9% above median |
| Obsarox | Deferasirox | 125 mg | Tablet | 28's | 100144 | PKR 6,406.21 | PKR 228.79/tablet | 58% above median |
| Obsarox | Deferasirox | 250 mg | Tablet | 28's | 100145 | PKR 10,603.28 | PKR 378.69/tablet | 26% above median |
| Obsarox | Deferasirox | 250 mg | Tablet | 1's | 100145 | PKR 377.15 | PKR 377.15/tablet | 25% above median |
| Obsarox | Deferasirox | 500 mg | Tablet | 28's | 100146 | PKR 17,599.58 | PKR 628.56/tablet | 20% above median |
| Obzinq | Zinc | 20 mg | Tablet | 10's | 096315 | PKR 76.92 | PKR 7.69/tablet | 21% below median |
| Obzitic | Linezolid | 600 mg | Tablet | 12's | 100157 | PKR 5,352.05 | PKR 446.00/tablet | 13% above median |
| Obzitic | Linezolid | 600 mg | Tablet | 10's | 100157 | PKR 4,460.04 | PKR 446.00/tablet | 13% above median |
| Ondaset | Ondansetron | 4 mg | Tablet | 10's | 097195 | PKR 828.55 | PKR 82.86/tablet | 10% below median |
| Ondaset | Ondansetron | 4 mg | Tablet | 1's | 097195 | PKR 82.85 | PKR 82.85/tablet | 10% below median |
| Ondaset | Ondansetron | 8 mg | Tablet | 10's | 097196 | PKR 1,380.92 | PKR 138.09/tablet | 17% below median |
| Ondaset | Ondansetron | 8 mg | Tablet | 1's | 097196 | PKR 138.09 | PKR 138.09/tablet | 17% below median |
| Ondaset | Ondansetron | 4 mg/5 mL | Oral solution | 50ml | 118325 | PKR 1,046.94 | PKR 20.94/mL | Near median |
| Onem | Imipenem + Cilastatin | 500 mg + 500 mg | IV injection | 1's | 098674 | PKR 1,622.15 | PKR 1,622.15/vial/unit | 5% above median |
| Ovafin | Clomifene citrate | 50 mg | Tablet | 10's | 104225 | PKR 493.77 | PKR 49.38/tablet | 19% above median |
| Plan Pill | Levonorgestrel | 0.15 mg | Tablet | 84's | 096246 | PKR 152.87 | PKR 1.82/tablet | 17% below median |
| Plan Pill | Levonorgestrel | 0.15 mg | Tablet | 28's | 096246 | PKR 61.16 | PKR 2.18/tablet | 20% above median |
| Ronidazole | Metronidazole | 200 mg | Tablet | 20 x10's | 098916 | PKR 378.50 | PKR 1.89/tablet | 12% below median |
| Ronidazole | Metronidazole | 400 mg | Tablet | 20's | 098917 | PKR 56.78 | PKR 2.84/tablet | 6% below median |
| Roxyquin | Hydroxychloroquine | 200 mg | Tablet | 30's | 100172 | PKR 565.37 | PKR 18.85/tablet | 30% above median |
| Sepidyl | Chlorhexidine gluconate | 7.1% w/w (equiv. chlorhexidine 4% w/w) | Gel | 10 gm | 084774 | PKR 97.74 | PKR 9.77/g | No comparator |
| Sepidyl | Chlorhexidine | 4% w/w | Gel | 15 gm | 084774 | PKR 147.61 | PKR 9.84/g | No comparator |
| Sepidyl | Chlorhexidine gluconate | 7.1% w/w (eq. chlorhexidine 4% w/w) | Gel | 7 x 3gm | 084774 | PKR 193.48 | PKR 9.21/g | 8% below median |
| Sepidyl | Chlorhexidine gluconate | 7.1% w/w (eq. chlorhexidine 4% w/w) | Gel | 3 gm | 084774 | PKR 29.92 | PKR 9.97/g | Near median |
| Sepidyl | Chlorhexidine gluconate | 7.1% w/w (eq. chlorhexidine 4% w/w) | Gel | 5 gm | 084774 | PKR 49.87 | PKR 9.97/g | Near median |
| Sofhep | Sofosbuvir | 400 mg | Tablet | 28's | 089073 | PKR 11,704.67 | PKR 418.02/tablet | Near median |
| Sofvel 400mg | Sofosbuvir | 400 mg | Tablet | 28's | 089074 | PKR 20,598.24 | PKR 735.65/tablet | 72% above median |
| Sporanox | Itraconazole | 100 mg | Capsule | 1x4's | 012647 | PKR 864.68 | PKR 216.17/capsule | 50% above median |
| Taklida | Tacrolimus | 0.5 mg | Capsule | 3 x10's | 097129 | PKR 1,401.17 | PKR 46.71/capsule | 19% below median |
| Taklida | Tacrolimus | 0.5 mg | Capsule | 1 x10's | 097129 | PKR 507.67 | PKR 50.77/capsule | 12% below median |
| Taklida | Tacrolimus | 1 mg | Capsule | 3 x10's | 097130 | PKR 2,335.29 | PKR 77.84/capsule | 20% below median |
| Taklida | Tacrolimus | 1 mg | Capsule | 1 x10's | 097130 | PKR 846.12 | PKR 84.61/capsule | 13% below median |
| Taklida | Tacrolimus | 5 mg | Capsule | 1 x10's | 097131 | PKR 4,230.59 | PKR 423.06/capsule | 17% below median |
| Tenaspin | Tenofovir disoproxil | 300 mg | Tablet | 30's | 100179 | PKR 7,024.99 | PKR 234.17/tablet | Near median |
| Trimzol | Clotrimazole | 10 mg | Cream | 10gm | 090849 | PKR 62.13 | PKR 6.21/g | 32% below median |
| Trimzol-H | Clotrimazole + Hydrocortisone | 10 mg + 10 mg | Cream | 30gm | 090850 | PKR 336.23 | PKR 11.21/g | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.
